Promedior Adds Howard J. Weisman to Board of Directors
LEXINGTON, Mass., June 19, 2013 — Promedior, Inc., a clinical-stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that Howard J. Weisman has been appointed to the company's Board of Directors. Mr. Weisman is an accomplished entrepreneur and pharmaceutical company executive who brings a diversity of experience leading the growth of a number of companies and businesses in the life sciences industry
"We are very excited that Howard has joined our Board at this important time in our growth, particularly as we advance our lead clinical programs," said Suzanne L. Bruhn, PhD, President and Chief Executive Officer of Promedior. "Howard's leadership and insight in the biotechnology and pharmaceutical industries will be a tremendous asset, and we are fortunate to have him as part of Promedior's leadership team."
An accomplished entrepreneur in the life sciences industry, Mr. Weisman is currently President and Chief Executive Officer at Seventh Sense Biosystems. Prior to joining Seventh Sense, he was the founder, Chairman and Chief Executive Officer of EKR Therapeutics, a specialty pharmaceutical company focused in the hospital critical care market. Mr. Weisman was also co-founder of ESP Pharma where he served as a director in addition to the company's President and Chief Operating Officer until its sale to PDL Biopharma in 2005. He began his career in sales and marketing at Merck and Co., Inc. and later moved to Parke-Davis where he launched that company's diabetes franchise in 1997. Mr. Weisman graduated with a BA in Chemistry from Rutgers University.
"Promedior's novel therapeutic approach opens up new opportunities to treat a wide range of serious fibrotic diseases for which there are no or few approved therapies. Promedior has assembled a team of highly experienced scientists, drug developers and business professionals and I am honored to contribute my experience and insights as the company continues its impressive advancements both clinically and commercially," said Mr. Weisman.
Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with excessive scar tissue, compromising function and ultimately leading to organ failure. Promedior's proprietary platform is based upon Pentraxin-2, an endogenous human protein that is specifically active at the site of tissue damage and works as an agonist, potentially preventing and reversing fibrosis.
Promedior has successfully advanced its lead therapeutic candidate in human clinical trials and is initially focused on rare fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and myelofibrosis. Promedior is backed by leading global healthcare venture investors, has a significant intellectual property estate relating to the discoveries and applications of Pentraxin-2 therapeutics and is led by an experienced management team. For additional information about Promedior, please visit www.promedior.com
The Yates Network